HSD3B1基因突变对去势抵抗型前列腺癌发生的影响  

Effects of HSD3B1 gene mutation on castration-resistant prostate cancer

作　　者：吴刚[1] 吴登龙[1] 黄盛松[1] 卞崔冬[1] 袁涛[1] 桂亚平[1] 吴旻[1] 张琪敏[1] 李军亮[1] 刘博[1] 赵鑫[1] 

机构地区：[1]同济大学附属同济医院泌尿外科,上海200065

出　　处：《临床泌尿外科杂志》2014年第12期1045-1048,共4页Journal of Clinical Urology

基　　金：国家自然科学基金面上项目(编号81172426);上海市教育委员会科研创新项目(编号12ZZ034)

摘　　要：目的：评估HSD3B1基因1245位点突变在去势抵抗型前列腺癌（castration-resistant prostate cancer,CRPC）发生中的作用。方法：回顾性分析2004年1月~2011年1月在我院行睾丸切除术的103例前列腺癌患者临床资料,其中HSD3B1基因1245位点突变18例。依据位点突变结果,将103例患者分为突变组及正常对照组,分别比较两组的PSA下降一半时间、CRPC形成率、CRPC形成时间、死亡率及生存时间等。结果：两组术前指标无异质性。突变组在CRPC形成率方面较对照组高,差异有统计学意义;但在PSA下降一半时间、CRPC形成时间、死亡率及生存时间等方面差异无统计学意义。结论：HSD3B1基因1245位点突变可提高CRPC形成率,但并没有缩短患者的生存时间及增加患者的死亡风险。HSD3B1基因1245位点突变是否会对CRPC将来的治疗带来改变,尚需进一步研究。Objective：To identify the effect of point mutation of HSD3B1 gene on castration-resistant prostate cancer（CRPC）.Method：From January 2004 to January 2011,a total of 103 consecutive patients diagnosed with prostate cancer were included in this study and treated with gonadal testosterone（T）deprivation therapy.Of these,18 patients undergoing point mutation at HSD3B1（1245C）were considered as mutation group,while 85 patients with homozygous wild-type inheritance were regarded as normal group.PSA half-time（PSAT1/2）,rate of CRPC formation,time forming CRPC and death rate were obtained at the follow-up.The perioperative data and postoperative outcomes were compared.The patients were retrospectively analyzed for survival time.Result：There were no significant differences between the two groups preoperatively.The CRPC formation observed in the normal group was significantly less than that of mutation group（P〈0.05）.There were no significant differences in PSA half-time,the occurrence of CRPC forming,time forming CRPC,survival time and death rate between two groups.Conclusion：The prostate cancer patients who have a point mutation of HSD3B1 gene do not have a shorter survival time and a higher death risk,but it is more likely to increase cancer risk of CRPC.Whether or not these results may have implications for the future treatment of CRPC remains to be studied.

关 键 词：前列腺肿瘤 去势抵抗型前列腺癌 HSD3B1基因突变 

分 类 号：R737.25[医药卫生—肿瘤]